- Home
- CG vs BMRN Comparison
CG vs BMRN Comparison
Compare CG & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CG
- BMRN
- Stock Information
- Founded
- CG 1987
- BMRN 1996
- Country
- CG United States
- BMRN United States
- Employees
- CG N/A
- BMRN N/A
- Industry
- CG Investment Managers
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- CG Finance
- BMRN Health Care
- Exchange
- CG Nasdaq
- BMRN Nasdaq
- Market Cap
- CG 14.0B
- BMRN 12.1B
- IPO Year
- CG 2012
- BMRN 1999
- Fundamental
- Price
- CG $46.86
- BMRN $55.00
- Analyst Decision
- CG Hold
- BMRN Buy
- Analyst Count
- CG 15
- BMRN 22
- Target Price
- CG $48.54
- BMRN $93.43
- AVG Volume (30 Days)
- CG 2.0M
- BMRN 2.2M
- Earning Date
- CG 08-04-2025
- BMRN 08-04-2025
- Dividend Yield
- CG 2.99%
- BMRN N/A
- EPS Growth
- CG N/A
- BMRN 152.82
- EPS
- CG 2.94
- BMRN 2.71
- Revenue
- CG $5,038,700,000.00
- BMRN $2,950,227,000.00
- Revenue This Year
- CG N/A
- BMRN $12.23
- Revenue Next Year
- CG $20.60
- BMRN $9.99
- P/E Ratio
- CG $15.99
- BMRN $20.29
- Revenue Growth
- CG 127.13
- BMRN 19.36
- 52 Week Low
- CG $33.02
- BMRN $52.93
- 52 Week High
- CG $57.50
- BMRN $94.85
- Technical
- Relative Strength Index (RSI)
- CG 57.21
- BMRN 35.12
- Support Level
- CG $45.68
- BMRN $54.46
- Resistance Level
- CG $47.89
- BMRN $58.17
- Average True Range (ATR)
- CG 1.16
- BMRN 1.39
- MACD
- CG -0.11
- BMRN -0.04
- Stochastic Oscillator
- CG 71.11
- BMRN 13.08
About CG The Carlyle Group Inc.
The Carlyle Group is one of the world's largest alternative-asset managers, with $447.4 billion in total AUM, including $313.6 billion in fee-earning AUM, at the end of September 2024. The company has three core business segments: private equity, which includes private equity, real estate, infrastructure, and natural resources funds (accounting for 33% of fee-earning AUM and 57% of base management fees during 2023), global credit (51% and 27%) and investment solutions (16% and 16%). The firm primarily serves institutional investors and high-net-worth individuals. Carlyle operates through 29 offices across five continents, serving more than 2,900 active carry fund investors from 88 countries.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.